MiniMed 780G: high-fat-meal strategies in crossover study
What this study tests
A completed Greek randomized crossover study enrolled 20 adults with T1D to compare three supervised high-fat-meal strategies. Despite a title naming 640G and 780G, the protocol describes using the same 780G pump in open- and closed-loop modes. No results are posted.
Editorial review: . 16 September review-note archive (earlier notes may not cover later changes).
Registry checked: 2026-09-17. Registry’s own update: 2026-08-25.
Most recent recorded citation date: 2026-08-25. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. Review coverage and open work · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults with T1D for at least 12 months, insulin-pump use for at least six months and recent HbA1c at or below 8%. The description specifies MiniMed 780G users taking aspart or lispro. Exclusions include specified diabetes complications, gastroparesis or malabsorption, gastrointestinal surgery and medicines affecting gastrointestinal motility. The age field starts at 18, while the narrative says over 18. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results are posted in ClinicalTrials.gov as of 17 September 2026. Registered endpoints and procedures are study plans, not evidence of benefit or safety.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the 16 September review-note archive and current review coverage. Later changes and new records may not appear in the earlier notes. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Serum post-meal glucose incremental area under the curve during the first four hours after the standardized meal.
The full picture
The registry classifies this as an open-label, randomized crossover intervention study with 20 actual participants and a site in Athens, Greece. The protocol describes three supervised meal visits in the same people, comparing an open-loop dual-wave approach, an automated-mode standard meal bolus, and an automated-mode approach with a supplementary bolus. Study-specific dose formulas are not reproduced here.1
The title and brief summary name MiniMed 640G versus 780G, but the detailed protocol says all participants use one 780G pump, with automation disabled for the open-loop condition. This record therefore describes comparisons of modes and meal-management strategies, not a confirmed head-to-head trial of two distinct pump models.1
The primary endpoint is the four-hour serum-glucose incremental area under the curve. The narrative also proposes CGM observation up to eight hours and a noninferiority analysis, but the public record gives no numerical noninferiority margin. These are planned assessments, not reported results.1
The registry lists actual start on 30 June 2025 and actual primary and study completion on 15 December 2025. The first submission was 21 August 2026, and the first posting and latest update were 25 August 2026, after completion. This retrospective registration limits assurance that the publicly registered plan preceded the study.1
No results are posted. The structured minimum age is 18, while the narrative describes people older than 18; that boundary remains unresolved. Eligibility also limits the cohort to experienced pump users with HbA1c at or below 8% and excludes several complications. Completion does not establish which strategy works better or is safer.1
References
Sources
- [1]Comparative Study of the Postprandial Glycemic Profile After Consumption of a High-fat Meal (Pizza) Between the Open-loop System (Medtronic MiniMed 640G) and the Hybrid Closed-loop System (Medtronic MiniMed 780G) in Patients With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Pumps. · Trial registry · 2026-08-25 — Original registry protocol, eligibility, outcomes and status checked 17 September 2026. Citation date is the last posted registry update, not a results publication.